Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HLA-A*0201 Positive Cells Present”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Ended earlyNCT02770820
What this trial is testing

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaEBV-Positive Neoplastic Cells PresentHLA-A*0201 Positive Cells Present+2 more
Fred Hutchinson Cancer Center 9
Testing effectiveness (Phase 2)Ended earlyNCT01640301
What this trial is testing

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Who this might be right for
Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia+5 more
Fred Hutchinson Cancer Center 47
Testing effectiveness (Phase 2)Looking for participantsNCT06942442
What this trial is testing

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Who this might be right for
HLA-A*0201 Positive Cells PresentClear Cell Sarcoma (CCS)
Sarcoma Alliance for Research through Collaboration 47
Early research (Phase 1)Ended earlyNCT03240861
What this trial is testing

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Who this might be right for
HLA-A*0201 Positive Cells PresentLocally Advanced Malignant NeoplasmNY-ESO-1 Positive+2 more
Jonsson Comprehensive Cancer Center 5
Testing effectiveness (Phase 2)Study completedNCT02396134
What this trial is testing

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+11 more
City of Hope Medical Center 61
Testing effectiveness (Phase 2)Ended earlyNCT02408016
What this trial is testing

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Who this might be right for
Advanced Pleural Malignant MesotheliomaHLA-A*0201 Positive Cells PresentRecurrent Non-Small Cell Lung Carcinoma+8 more
Fred Hutchinson Cancer Center 11
Early research (Phase 1)Study completedNCT03450122
What this trial is testing

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Who this might be right for
HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Myxoid Liposarcoma+1 more
M.D. Anderson Cancer Center 15
Testing effectiveness (Phase 2)Study completedNCT03318900
What this trial is testing

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Who this might be right for
COL6A3 PositiveHLA-A*0201 Positive Cells PresentPRAME Positive+1 more
M.D. Anderson Cancer Center 5
Early research (Phase 1)WithdrawnNCT03506802
What this trial is testing

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Who this might be right for
HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Plasma Cell Myeloma+1 more
Jonsson Comprehensive Cancer Center